BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

940 related articles for article (PubMed ID: 21524610)

  • 1. Oral Candida isolates among HIV-infected subjects in Nigeria.
    Nweze EI; Ogbonnaya UL
    J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients.
    Nadagir SD; Chunchanur SK; Halesh LH; Yasmeen K; Chandrasekhar MR; Patil BS
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):492-5. PubMed ID: 18564689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.
    Costa CR; de Lemos JA; Passos XS; de Araújo CR; Cohen AJ; Souza LK; Silva Mdo R
    Mycopathologia; 2006 Jul; 162(1):45-50. PubMed ID: 16830191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey.
    Kuzucu C; Durmaz R; Otlu B; Aktas E; Gulcan H; Cizmeci Z
    New Microbiol; 2008 Jul; 31(3):401-8. PubMed ID: 18843896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic analysis of oral Candida carriage, distribution, and antifungal susceptibility in HIV-infected patients during the first year of highly active antiretroviral therapy in Guangxi, China.
    Jiang L; Yong X; Li R; Peng Y; Liu W; Qin Q; Zhang L; Liu Z; Liang H; Tao R
    J Oral Pathol Med; 2014 Oct; 43(9):696-703. PubMed ID: 24931443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
    Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
    J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients.
    Maninder J; Usha A
    J Commun Dis; 2008 Sep; 40(3):177-81. PubMed ID: 19245155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of candida isolates from denture-related stomatitis to antifungal agents in vitro.
    Dorocka-Bobkowska B; Konopka K
    Int J Prosthodont; 2007; 20(5):504-6. PubMed ID: 17944341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.
    Kirkpatrick WR; Revankar SG; Mcatee RK; Lopez-Ribot JL; Fothergill AW; McCarthy DI; Sanche SE; Cantu RA; Rinaldi MG; Patterson TF
    J Clin Microbiol; 1998 Oct; 36(10):3007-12. PubMed ID: 9738058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients.
    Chunchanur SK; Nadgir SD; Halesh LH; Patil BS; Kausar Y; Chandrasekhar MR
    Indian J Pathol Microbiol; 2009; 52(4):501-4. PubMed ID: 19805956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
    Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
    Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing and the Clinical Laboratory Standards Institute BMD method for non-Candida albicans and non-C. tropicalis bloodstream isolates from eleven tertiary hospitals in São Paulo state, Brazil.
    Purisco SU; Martins MA; Szeszs MW; Castro e Silva DM; Pukinskas SR; Bonfietti LX; Baez AA; Melhem MS
    FEMS Yeast Res; 2012 Dec; 12(8):890-6. PubMed ID: 22883021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.
    Enwuru CA; Ogunledun A; Idika N; Enwuru NV; Ogbonna F; Aniedobe M; Adeiga A
    Afr Health Sci; 2008 Sep; 8(3):142-8. PubMed ID: 19357740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.